Cafran

Quick links to important sections

Cafran

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cafran

Quick Facts

Property Description
Active ingredient Cefotaxime
Form Sterile powder for injection
Pharmacological class Third-generation Cephalosporin, Beta-lactam antibiotic
Common use Clearing systemic bacterial infections
Origin Semi-synthetic

What Type of Medicine is Cafran, and What is its Composition?

Cafran is a prescription-only medicine utilizing Cefotaxime as its active ingredient, which is a drug clinically recognized for its efficacy against Gram-negative bacteria and its stability against certain bacterial enzymes. The compound is classified as a third-generation cephalosporin antibiotic, a position within the beta-lactam antibiotic family that distinguishes it from older agents, providing an expanded range of bacterial coverage. The specific preparation contains Cefotaxime Sodium, a semi-synthetic derivative optimized for rapid dissolution, ensuring high solubility for its intended parenteral administration. Cafran is supplied as a sterile powder for injection, a presentation that is characteristic of antibiotics intended for hospital or specialized clinical settings where systemic delivery is required.

What is the General Purpose of Cafran?

The core purpose of Cafran is to provide definitive treatment by achieving bactericidal action against susceptible pathogens causing systemic infection. This action involves the ability to interfere directly with the integrity of the bacterial cell. Cefotaxime serves as an agent for treating serious infections by disrupting the bacterial cell wall. The medication is intended to provide a systematic method to clear severe bacterial infections, such as hospital-acquired infections or complex sepsis cases. The drug specifically targets and inhibits the essential process of cell wall synthesis, ensuring the eradication of the infectious threat.

Regulatory References

  1. Cefotaxime Injection: MedlinePlus Drug Information

What side effects are possible with Cafran?

Possible Side Effects and Safety Information

Cafran's (Cefotaxime) safety profile, as documented in official regulatory labeling, is classified by the frequency and body system affected. Adverse reactions are grouped using standardized System-Organ Class (SOC) categories, highlighting potential effects on the blood, nervous, immune, and gastrointestinal systems.

Adverse Reaction Frequency
Very Common (occurs in geq1/10 patients): Pain at the injection site.
Common (occurs in geq1/100 to <1/10 patients): Skin reactions such as rash and pruritus, fever, diarrhea, nausea, vomiting, and local inflammation/tenderness at the injection site.
Uncommon (occurs in geq1/1,000 to <1/100 patients): Changes in blood cell counts (leukopenia, thrombocytopenia), convulsions/seizures, transient elevations in liver enzymes, and decreases in renal function.

Serious adverse reactions officially documented include potentially life-threatening hypersensitivity responses like Anaphylaxis and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS). The drug is also associated with Clostridium difficile-associated diarrhea (CDAD), which can occur during or after treatment, and the risk of encephalopathy (changes in brain function) primarily when high doses are used, especially in patients with impaired renal function.

Safety notes specify that blood-related effects like neutropenia may be observed with long-term use (typically over 7 to 10 days). Additionally, the label notes that patients with renal impairment or older adults may be at increased risk of toxic reactions due to reduced drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

A Cafran (Cefotaxime) overdose primarily affects the Central Nervous System (CNS) and may result in serious neurological manifestations. Documented presentations include CNS excitation conditions, myoclonia (involuntary muscle twitching), and general symptoms such as gastrointestinal distress. The most severe outcomes listed in regulatory documents are convulsions (seizures) and reversible encephalopathy (impairment of brain function). The risk of these severe effects is significantly increased in individuals with severely restricted kidney function and in those with pre-existing epilepsy or meningitis. This risk is related to the impaired elimination of the drug at high doses.


When Immediate Medical Help Is Required

It is mandatory to seek emergency medical attention immediately if an overdose is suspected or if severe, life-threatening symptoms such as convulsions occur. The official regulatory instruction is that the drug must be discontinued right away, and adequate emergency measures must be initiated. Treatment is supportive as no specific antidote is known. Management focuses on treating symptoms and, when necessary, utilizing procedures like hemodialysis or peritoneal dialysis to help reduce the drug's plasma concentration in the body.

Therapeutic Uses of Cafran

What Cafran Treats: Main Uses and Benefits

Cafran is commonly used as therapeutic support in acute, serious clinical contexts, addressing conditions where heightened bacterial activity causes symptoms related to systemic imbalance and organ-specific functional stress. The medication generally provides supportive relief that helps patients cope more steadily with difficult episodes.

The medicine is used to treat a range of infections caused by susceptible bacteria, which typically includes widespread pneumonia, other serious lower respiratory tract infections, conditions involving inflammatory or irritative processes in the central nervous system such as meningitis, and bloodstream infections like septicemia. The primary benefit is the support it offers in addressing symptoms linked to organ-specific functional stress and assisting with maintaining functional stability when symptoms are more noticeable.

This application is also relevant for easing symptoms that interfere with daily functioning in conditions presenting with systemic or localized discomfort in the intra-abdominal, bone and joint, and urinary tract regions. The support provided contributes to improved comfort during periods of heightened physiological strain.

Quick Fact: Support for Acute Systemic Distress
Common Use Context Applied in clinical settings that involve acute or unstable symptom patterns, when short-term symptomatic assistance is needed.
Symptom Focus Helps address symptoms related to acute fever and systemic imbalance caused by bacterial presence.
Main Benefit Contributes to improved comfort during periods of heightened physiological strain.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Cafran (Cefotaxime) is an antibiotic whose use is defined by strict regulatory-based rules concerning patient eligibility and pre-existing conditions. Its eligibility is established for adults, adolescents, children, and neonates, although specific dosage schedules apply to different age groups.

Contraindicated Populations

Cafran is strictly contraindicated for individuals with a known or suspected hypersensitivity to Cefotaxime or any other cephalosporin antibiotic. Extreme caution is required for patients with a history of immediate-type hypersensitivity to penicillin due to the risk of allergic cross-reactions. For formulations containing Lidocaine, use is prohibited in infants less than 30 months of age and in patients with known Lidocaine allergy or severe heart block.

Conditional and Restricted Use

Population / Condition Eligibility Constraint (Regulatory Basis)
Impaired Renal Function Use requires a reduced dosage based on calculated creatinine clearance, as high concentrations may occur in severe renal failure.
Pregnancy/Lactation Conditional use only; safety in human pregnancy is not established, and the drug is excreted into human milk, requiring a benefit-risk assessment.
Geriatric Patients Caution is required due to the higher likelihood of age-related reductions in kidney function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cafran, which contains the active substance Cefotaxime, has documented interactions primarily concerning medicines that can affect kidney function and specific blood components. The regulatory documentation requires careful assessment when this medicine is co-administered with certain other products.

Interaction Domain Relevant Interacting Agents
Nephrotoxic Agents Probenecid, Aminoglycosides, Loop Diuretics (e.g., Furosemide)
Anticoagulants Warfarin and other oral anticoagulants

Co-administration with nephrotoxic agents, such as Aminoglycosides or Loop Diuretics, increases the risk of negative effects on kidney function, and regulatory information notes the need for close monitoring of kidney function tests. The medicine Probenecid can increase the concentration of Cafran in the bloodstream by altering its elimination, leading to higher systemic exposure. The combination with oral anticoagulants, including Warfarin, requires routine monitoring of blood clotting tests (e.g., International Normalized Ratio or INR) because of a potential for the medicine to enhance the anticoagulant effect and increase the risk of bleeding.

Furthermore, Cafran can affect the results of certain laboratory tests, including the Coombs' test and tests for urinary glucose using copper reduction methods, which must be considered when interpreting these results. No specific timing-based rules or food-based restrictions are officially documented for this product.

Mechanism of Action

Synaptic Serotonin Level Modulation

Cafran's pharmacodynamic action is initiated by its selective, high-affinity binding to the Serotonin Transporter (SERT) protein located on the presynaptic neuronal membrane. This interaction functionally inhibits the transporter, thereby blocking the rapid reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft. This acute molecular event leads to an elevated and sustained concentration of extracellular 5-HT, influencing the initial phase of central neural signaling.


Neuroplastic Pathway Adaptation

Sustained elevation of 5-HT triggers secondary, time-dependent cellular processes across the affected pathways. This mechanistic domain engages neuroplastic feedback, resulting in the gradual desensitization and down-regulation of certain central 5-HT autoreceptors and subsequent alterations in postsynaptic receptor distribution. This prolonged modulation contributes to persistent changes in activity levels within neural circuits associated with emotional regulation.


Central Physiological Modulation

The long-term adaptation process influences the response patterns of physiological systems operating at elevated activity levels and modifies the effects produced by this altered mediator signaling. These systematic adjustments delineate the range of systemic physiological effects produced by the drug's mechanism.

Dosage and Administration Information

Cafran (Cefotaxime) is administered in a specialized clinical environment, as its delivery is exclusively parenteral—meaning it is given by injection into a vein (Intravenous or IV) or into a large muscle (Intramuscular or IM). It is supplied as a sterile powder and must be reconstituted (diluted) with an appropriate sterile fluid prior to administration.

The standard adult dosing schedule is highly dependent on the condition being addressed. The typical daily range is 2 g to 6 g, which is divided into equal amounts for fixed administration intervals. For severe or life-threatening conditions, the frequency is often increased, and the total daily dose may reach a maximum of 12 g.

The administration frequency is precisely timed, ranging from every 4 hours (q4h) for the most serious conditions to every 12 hours (q12h) for less complicated use patterns. IV administration, the preferred route for severe cases, requires specific procedural conditions: the injection must be administered slowly, often over a period of 3 to 5 minutes for a bolus or 20 to 60 minutes for an infusion.

Age- and Population-Specific Rules

Population Official Usage Rule
Severe Renal Impairment The dose must be halved (reduced by 50%) after the initial loading dose.
Pediatric Patients Dosing is calculated based on body weight (mg/kg/day), with amounts divided for administration every 6 to 8 hours.

Treatment duration is not fixed but is typically maintained for a minimum of 48 to 72 hours after clinical improvement is demonstrated.

Recent Clinical Evidence

Cafran is a third-generation cephalosporin antibiotic, with the active ingredient being Cefotaxime. Recent clinical evidence continues to support its role as a broad-spectrum, bactericidal agent for treating a wide range of serious bacterial infections, often administered intravenously or intramuscularly.

Efficacy in Severe Infections

Clinical trials and retrospective studies consistently demonstrate the efficacy of Cafran (Cefotaxime) in achieving satisfactory clinical and bacteriological success rates (often between 75% and 100%) across various infection types. Key areas of demonstrated effectiveness include:

  • Lower Respiratory Tract Infections: Successful outcomes are frequently observed in treating conditions such as pneumonia, particularly those caused by susceptible Gram-negative organisms and Streptococcus pneumoniae.
  • Meningitis: Cafran is a standard treatment option for bacterial meningitis in both adults and children, often used at higher doses to ensure adequate penetration into the cerebrospinal fluid.
  • Other Serious Infections: The drug maintains a crucial role in managing severe intra-abdominal infections, septicemia, and complicated urinary tract infections caused by susceptible organisms.

Safety Profile and Comparative Data

Cafran is generally well-tolerated. The most commonly reported side effects include injection site reactions (pain, swelling), gastrointestinal issues (diarrhea, nausea), and hypersensitivity reactions. High doses, particularly in patients with impaired kidney function, may potentially lead to neurotoxicity, such as encephalopathy or seizures, underscoring the importance of careful dosing and monitoring.

Comparative studies have shown Cafran to be therapeutically equivalent in efficacy to other widely used third-generation cephalosporins. Furthermore, ongoing research continues to evaluate its clinical impact, including studies comparing its use to other antibiotics in critical care settings for conditions like pneumonia and bloodstream infections, and examining its potential impact on the emergence of multidrug-resistant bacteria.

Key Studies & References

  1. Cefotaxime - StatPearls - NCBI Bookshelf - NIH
  2. Meningitis Treatment & Management - Medscape Reference
  3. Cefotaxime: A Reappraisal in Lower Respiratory Tract Infections - F1000Research

Frequently Asked Questions (FAQ)

Common questions about Cafran (FAQ)

Q: What is the main difference between Cafran and other similar medicines?

A: Cafran contains Cefotaxime, a third-generation cephalosporin antibiotic. A difference noted in official prescribing information, compared to some similar medicines in this class, is its relatively short half-life. Because of this, the medicine is typically given more frequently throughout the day to maintain effective levels in the body.

Q: How long does it typically take to start noticing the effects of Cafran?

A: Official sources indicate that clinical improvement is generally noticed during the initial days of treatment with this medicine. If symptoms do not improve or begin to worsen after a few days, it is recommended that a healthcare provider be consulted.

Q: Does Cafran continue to work effectively over a long period of time?

A: The official product labeling mentions that studies found no evidence of drug accumulation in the body following repeated administration over a period of 14 days. This may be interpreted as showing that the medicine maintains its pharmacological profile over the typical acute treatment duration.

Q: Is Cafran a safe medication to take every day?

A: Cafran is designed as an acute-use medicine to treat serious bacterial infections, and it is often administered multiple times per day for a specific, limited duration. Official prescribing information does not list it as a medication intended for chronic, long-term, daily use.

Q: Can Cafran cause long-term side effects that appear later?

A: Regulatory warnings state that prolonged treatment, usually defined as more than 10 days, has been associated with specific adverse effects, such as granulocytopenia (a type of reduction in white blood cells). Such extended treatment may involve the need for blood monitoring.

Q: Is it normal to feel [vague side effect, e.g., tired, dizzy] when first starting Cafran?

A: While general tiredness is not explicitly listed among the most common adverse effects, dizziness is noted as a possible side effect that may affect some individuals. Official information also warns of potential changes in blood cell counts, which are general effects that could potentially contribute to malaise.

Q: Is Cafran known to interact negatively with over-the-counter pain relievers?

A: Official warnings state that caution is necessary when the medicine is co-administered with certain non-steroidal anti-inflammatory drugs (NSAIDs), which include some common pain relievers. This combination may increase the risk of adverse effects on kidney function.

Q: Is it safe to consume alcohol in moderation while taking Cafran?

A: Official product information generally does not list a direct chemical interaction with alcohol. However, consumption of alcohol may enhance some central nervous system side effects of the medicine, such as dizziness, so caution is advised.

Q: Does Cafran affect birth control or family planning methods?

A: Regulatory information indicates that this medicine may decrease the effectiveness of certain hormonal contraceptives, including birth control pills, patches, rings, and injections. It is advised to consult a healthcare professional regarding the potential need for alternative or additional contraceptive methods.

Q: Is Cafran addictive, or can the body become dependent on it?

A: Cafran belongs to the cephalosporin class of antibiotics. According to official drug information, there are no regulatory warnings or evidence indicating that it is associated with addiction or physical dependence.

Q: Does Cafran have a generic version available?

A: Yes, the active ingredient is Cefotaxime Sodium, which is a widely available and approved generic drug. The generic form is supplied by multiple manufacturers in addition to the brand name product.

Q: Is Cafran considered safe to use during pregnancy?

A: The active ingredient, Cefotaxime, is generally classified as Pregnancy Category B, meaning animal studies have not demonstrated a risk to the fetus. Determining the use of this medicine during human pregnancy involves a careful benefit-risk assessment, which should be done by a qualified professional.

Q: Can Cafran be used while breastfeeding?

A: Regulatory information indicates that the drug is excreted into human milk. Due to this potential transfer, caution is advised for its use while breastfeeding, and a careful benefit-risk assessment by a healthcare professional is necessary.

Q: What are the general rules for stopping Cafran treatment?

A: Official guidelines state that the full prescribed course of treatment is intended to be completed, even if symptoms begin to improve quickly. Stopping the treatment prematurely or skipping doses is associated with the risk of the infection returning and the bacteria developing resistance to the antibiotic.

Q: What should I do if Cafran does not seem to be working for me?

A: Official guidelines advise that if symptoms of the infection do not improve or if they get worse during the first few days of treatment, contacting a healthcare professional immediately is advised.

Q: Is there an age limit for who can use Cafran?

A: The medicine is generally eligible for use across all ages, including neonates, children, and adults. However, a strict prohibition (contraindication) exists for formulations containing the local anesthetic Lidocaine when used in infants younger than 30 months of age.

Q: Does taking Cafran require any special blood tests or monitoring?

A: Official documents note that monitoring of both kidney function and blood cell counts may be necessary during treatment. This monitoring is particularly important during prolonged courses of treatment or when the medicine is co-administered with drugs known to affect the kidneys.

Q: What is the risk of having a serious allergic reaction to Cafran?

A: Serious and potentially fatal allergic reactions (hypersensitivity) have been reported in official warnings. The medicine is strictly prohibited (contraindicated) for anyone with a known allergy to Cefotaxime or to the cephalosporin class of antibiotics.

Q: Does Cafran affect my ability to drive or operate machinery?

A: Regulatory warnings indicate that the medicine may cause dizziness in some individuals. Due to this potential effect, official guidance recommends caution regarding driving or operating heavy machinery, particularly before understanding the drug's effects.

Q: Can I take Cafran if I have known liver or kidney problems?

A: Official product information advises that caution is required if there is a history of liver disease. For patients with impaired kidney function, a professional dose adjustment (reduction) is necessary, as high concentrations of the drug may occur otherwise.

Q: What happens if I accidentally take two doses of Cafran close together?

A: The symptoms associated with accidental overdose may include gastrointestinal issues like nausea, vomiting, and diarrhea. In more severe cases, or cases of high dose, effects on the nervous system, such as convulsions, have been reported. Should an overdose be suspected, immediate medical attention is necessary.

Q: Is Cafran suitable for people with a history of heart issues?

A: Caution is advised during rapid administration, as this has been associated with potentially life-threatening heart rhythm changes (arrhythmias) in rare cases. Additionally, formulations that contain the anesthetic Lidocaine are strictly prohibited for patients with severe heart block.

Q: Is Cafran approved by [specific major regulatory body, e.g., the FDA, EMA]?

A: Yes, the active ingredient, Cefotaxime Sodium, has approved regulatory labeling for its use in treating bacterial infections in jurisdictions like the United States and other international regions.

Q: How long after stopping Cafran does it stay in your system?

A: The drug's elimination half-life is relatively short, approximately 1 to 1.5 hours in adults with normal kidney function. This half-life is the time it takes for half the drug to be eliminated from the body.

Q: Does Cafran cause changes in mood or sleep patterns?

A: Official warnings state that neurotoxicity is a possible adverse effect. High doses, especially in patients with reduced kidney function, may lead to encephalopathy (abnormal brain function), which can indirectly influence mental status and sleep.

Q: What research is available on Cafran and [broad population, e.g., older adults]?

A: Studies have not shown specific problems related only to older patients that would limit the usefulness of the medicine. However, official information advises caution and potential dose adjustment for older adults due to the increased likelihood of reduced kidney function associated with age.

Q: Does Cafran cause sun sensitivity or skin issues?

A: Official side effect lists commonly include skin reactions such as rash and pruritus (itching). While photosensitivity (increased sun sensitivity) may not be listed among the most common effects, the full prescribing information should be consulted for all warnings.

Q: Why is it important to keep taking Cafran even if my symptoms improve?

A: Official guidelines explain that completing the prescribed course is essential to ensure the infection is fully eradicated. Stopping treatment too soon or missing doses is associated with the risk of the infection returning and the bacteria developing resistance to the antibiotic.

Q: How is Cafran different from a traditional vitamin or dietary supplement?

A: Cafran is fundamentally different because it is a prescription-only medicine classified as an antibiotic, meaning its purpose is to actively kill bacteria and treat defined diseases. In contrast, vitamins and dietary supplements are not regulated or approved to treat specific bacterial infections.

Q: Is Cafran considered a 'new' drug or has it been used for a long time?

A: Cafran belongs to the third-generation cephalosporin class, which is a type of semi-synthetic antibiotic that has been available for clinical use for many years.

Q: Does Cafran contain gluten or any other common allergens?

A: The drug is Cefotaxime Sodium and is supplied as a sterile powder for injection. While it does contain ingredients like sodium citrate and dextrose, it is recommended that the full list of inactive ingredients be reviewed with a healthcare professional to check for any specific common allergens.

How should Cafran be stored and disposed of?

How to Store and Dispose of Cafran

Storage and disposal of Cafran (Cefotaxime) must adhere strictly to official regulatory conditions to maintain stability and ensure safety.

Storage Requirements

Product Form Temperature / Condition
Unreconstituted Powder Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), protected from light. Do not freeze.
Reconstituted Solution Use within 24 hours if kept at room temperature, or up to 7 to 10 days if stored under refrigeration (2 C to 8 C).
  • Packaging: The powder must remain in the original container to maintain light protection.
  • Child Safety: Keep Cafran out of the sight and reach of children.

Disposal

Any unused portion of the reconstituted solution must be immediately discarded. Expired product and related waste should be disposed of according to local pharmaceutical waste regulations, utilizing licensed take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cafran found in:

A-Z Index: